Enterprise value = Market value of equity + Market value of debt - Cash. EBITDA = Estimated by adding depreciation and amortization back to operating income (EBIT).
Emerging markets include; Anguilla, Antigua & Barbuda, Argentina, Azerbaijan, Bahamas, Bahrain, Bangladesh, Bermuda, Botswana, Brazil, British Virgin Islands, Bulgaria, Burkina Faso, Cambodia, Cameroon, Cayman Islands, Chile, China, Colombia, Costa Rica, Croatia, Curaçao, Dominican Republic, Ecuador, Egypt, Estonia, Falkland Islands, Gabon, Ghana, Greenland, Hong Kong, India, Indonesia, Israel, Ivory Coast, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Lithuania, Macau, Macedonia, Malawi, Malaysia, Mali, Marshall Islands, Mauritius, Mexico, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Netherlands Antilles, Niger, Nigeria, Oman, Pakistan, Palestinian Authority, Panama, Papua New Guinea, Peru, Philippines, Qatar, Romania, Russia, Saint Lucia, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, Solomon Islands, South Africa, South Korea, Sri Lanka, Sudan, Taiwan, Tanzania, Thailand, Togo, Trinidad & Tobago, Tunisia, Turks & Caicos Islands, Uganda, Ukraine, United Arab Emirates, Uruguay, Vietnam, Zambia, Zimbabwe.
Figures for years 2019 to 2024 were previously published by the source.
Citation formats
EV/EBITDA in the health and pharmaceuticals sector in emerging markets 2019-2026
For emerging markets worldwide, the average value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health and pharmaceuticals sector as of January 2026 was a multiple of approximately *. Companies operating in the ** industry saw the highest valuation multiple, with EV/EBITDA valued at over ***. While the * industry typically led in previous years, no data is available for 2026.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Leonard N. Stern School of Business. (January 5, 2026). Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2026, by industry [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 03, 2026, from /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. "Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2026, by industry." Chart. January 5, 2026. ÌÇÐÄÆƽâ°æ. Accessed August 03, 2026. /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. (2026). Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2026, by industry. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 03, 2026. /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business. "Average Ev/Ebitda Multiples in The Health and Pharmaceuticals Sector in Emerging Markets Worldwide from 2019 to 2026, by Industry." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 5 Jan 2026, /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
Leonard N. Stern School of Business, Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2026, by industry ÌÇÐÄÆƽâ°æ, /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/ (last visited August 03, 2026)
Average EV/EBITDA multiples in the health and pharmaceuticals sector in emerging markets worldwide from 2019 to 2026, by industry [Graph], Leonard N. Stern School of Business, January 5, 2026. [Online]. Available: /statistics/1030501/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-emerging-markets/
